AKBA · Nasdaq
It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.
Hover or tap a dot to see the filings behind that score.
Akebia Therapeutics, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the period ended June 30, 2023 (the “Form 10-Q”) by the prescribed due date without unreasonable effort or expense because of the circumstances described below. In the course of preparing its financial statements for the quarter ended June 30, 2023, the Company identified certain accounting errors relating to recording and reporting of return reserves for the Company’s product, Auryxia® (ferric citrate) (collectively, the “Return Reserve Errors”) in financial statements previously filed by the Company with the Securities and Exchange Commission (the “Commission”) for the fiscal years ended December 31, 2022, 2021 and 2020 and the quarter ended March 31, 2023. The Company requires additional time to complete its assessment of its internal control over financial reporting, and to prepare a complete and accurate Form 10-Q for the quarter ended June 30, 2023 due to the Company’s ongoing assessment of the Return Reserve Errors. The Company does not currently anticipate that the correction of the Return Reserve Errors will impact the Company’s previously issued 2023 Auryxia net product revenue guidance. In addition, based on its current operating plan, the Company believes that its cash resources as of June 30, 2023 will be sufficient to allow the Company to fund its current operating plan through at least the next twelve months from the date of this filing. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects. As a result of the foregoing, the Company requires additional time to complete the preparation and review of its financial statements and other disclosures in the Form 10-Q, and to complete its quarterly closing processes and procedures
NT 10-Q, filed 2023-08-10 · material weakness
Akebia Therapeutics, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the period ended June 30, 2023 (the “Form 10-Q”) by the prescribed due date without unreasonable effort or expense because of the circumstances described below. In the course of preparing its financial statements for the quarter ended June 30, 2023, the Company identified certain accounting errors relating to recording and reporting of return reserves for the Company’s product, Auryxia® (ferric citrate) (collectively, the “Return Reserve Errors”) in financial statements previously filed by the Company with the Securities and Exchange Commission (the “Commission”) for the fiscal years ended December 31, 2022, 2021 and 2020 and the quarter ended March 31, 2023. The Company requires additional time to complete its assessment of its internal control over financial reporting, and to prepare a complete and accurate Form 10-Q for the quarter ended June 30, 2023 due to the Company’s ongoing assessment of the Return Reserve Errors. The Company does not currently anticipate that the correction of the Return Reserve Errors will impact the Company’s previously issued 2023 Auryxia net product revenue guidance. In addition, based on its current operating plan, the Company believes that its cash resources as of June 30, 2023 will be sufficient to allow the Company to fund its current operating plan through at least the next twelve months from the date of this filing. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects. As a result of the foregoing, the Company requires additional time to complete the preparation and review of its financial statements and other disclosures in the Form 10-Q, and to complete its quarterly closing processes and procedures
reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.
Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.
See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.Every item above is a filing this company
made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not
investment advice